BMY - Bristol Myers 2seventy bio to face FDA AdCom for Abecma label expansion
2023-11-20 07:34:54 ET
More on Bristol-Myers
- Bristol Myers Squibb: Bright Future Ahead
- Bristol-Myers Squibb Company (BMY) Management Presents at Jefferies London Healthcare Conference (Transcript)
- Bristol-Myers Squibb Company (BMY) Management Presents at 2023 UBS BioPharma Conference (Transcript)
- FDA approves Bristol Myers lung cancer drug repotrectinib: report
- Bristol-Myers cut to Neutral as Cantor moves out of “value trap”
For further details see:
Bristol Myers, 2seventy bio to face FDA AdCom for Abecma label expansion